vs
Side-by-side financial comparison of INSTEEL INDUSTRIES INC (IIIN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $159.9M, roughly 1.1× INSTEEL INDUSTRIES INC). INSTEEL INDUSTRIES INC runs the higher net margin — 4.7% vs 1.6%, a 3.1% gap on every dollar of revenue. On growth, INSTEEL INDUSTRIES INC posted the faster year-over-year revenue change (23.3% vs 5.0%). Over the past eight quarters, INSTEEL INDUSTRIES INC's revenue compounded faster (12.0% CAGR vs -0.2%).
Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
IIIN vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $159.9M | $177.4M |
| Net Profit | $7.6M | $2.9M |
| Gross Margin | 11.3% | — |
| Operating Margin | 6.0% | 3.9% |
| Net Margin | 4.7% | 1.6% |
| Revenue YoY | 23.3% | 5.0% |
| Net Profit YoY | 602.4% | — |
| EPS (diluted) | $0.39 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $159.9M | $196.9M | ||
| Q3 25 | $177.4M | $179.5M | ||
| Q2 25 | $179.9M | $181.1M | ||
| Q1 25 | $160.7M | $168.9M | ||
| Q4 24 | $129.7M | $187.3M | ||
| Q3 24 | $134.3M | $168.6M | ||
| Q2 24 | $145.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $7.6M | — | ||
| Q3 25 | $14.6M | $5.4M | ||
| Q2 25 | $15.2M | $-4.8M | ||
| Q1 25 | $10.2M | $4.8M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $4.7M | $-143.5M | ||
| Q2 24 | $6.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 79.5% | ||
| Q3 25 | 16.1% | 80.9% | ||
| Q2 25 | 17.1% | 77.4% | ||
| Q1 25 | 15.3% | 79.7% | ||
| Q4 24 | 7.3% | 78.7% | ||
| Q3 24 | 9.1% | 76.9% | ||
| Q2 24 | 10.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.0% | 1.2% | ||
| Q3 25 | 10.8% | 3.5% | ||
| Q2 25 | 11.0% | 4.7% | ||
| Q1 25 | 8.3% | 1.2% | ||
| Q4 24 | 1.1% | 13.2% | ||
| Q3 24 | 4.5% | -82.8% | ||
| Q2 24 | 6.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 8.2% | 3.0% | ||
| Q2 25 | 8.4% | -2.7% | ||
| Q1 25 | 6.4% | 2.8% | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 3.5% | -85.1% | ||
| Q2 24 | 4.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.39 | $0.05 | ||
| Q3 25 | $0.74 | $0.12 | ||
| Q2 25 | $0.78 | $-0.11 | ||
| Q1 25 | $0.52 | $0.10 | ||
| Q4 24 | $0.06 | $0.38 | ||
| Q3 24 | $0.24 | $-3.11 | ||
| Q2 24 | $0.34 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.6M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $358.8M | $653.9M |
| Total Assets | $456.1M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $15.6M | $238.4M | ||
| Q3 25 | $38.6M | $246.3M | ||
| Q2 25 | $53.7M | $445.9M | ||
| Q1 25 | $28.4M | $493.6M | ||
| Q4 24 | $36.0M | $484.6M | ||
| Q3 24 | $111.5M | $453.8M | ||
| Q2 24 | $97.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $358.8M | $693.1M | ||
| Q3 25 | $371.5M | $727.2M | ||
| Q2 25 | $356.2M | $757.8M | ||
| Q1 25 | $341.4M | $798.5M | ||
| Q4 24 | $331.6M | $778.3M | ||
| Q3 24 | $350.9M | $749.6M | ||
| Q2 24 | $346.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $456.1M | $1.3B | ||
| Q3 25 | $462.6M | $1.3B | ||
| Q2 25 | $471.9M | $1.5B | ||
| Q1 25 | $421.9M | $1.6B | ||
| Q4 24 | $404.7M | $1.6B | ||
| Q3 24 | $422.6M | $1.5B | ||
| Q2 24 | $414.6M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-701.0K | — |
| Free Cash FlowOCF − Capex | $-2.2M | — |
| FCF MarginFCF / Revenue | -1.4% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $439.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-701.0K | $43.7M | ||
| Q3 25 | $-17.0M | $60.8M | ||
| Q2 25 | $28.5M | $12.0M | ||
| Q1 25 | $-3.3M | $35.5M | ||
| Q4 24 | $19.0M | $33.1M | ||
| Q3 24 | $16.2M | $53.9M | ||
| Q2 24 | $18.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-2.2M | $43.5M | ||
| Q3 25 | $-18.7M | $57.0M | ||
| Q2 25 | $26.9M | $9.3M | ||
| Q1 25 | $-5.5M | $26.9M | ||
| Q4 24 | $16.3M | $31.0M | ||
| Q3 24 | $14.5M | $49.8M | ||
| Q2 24 | $15.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -1.4% | 22.1% | ||
| Q3 25 | -10.6% | 31.7% | ||
| Q2 25 | 15.0% | 5.1% | ||
| Q1 25 | -3.5% | 15.9% | ||
| Q4 24 | 12.6% | 16.6% | ||
| Q3 24 | 10.8% | 29.6% | ||
| Q2 24 | 10.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 0.1% | ||
| Q3 25 | 1.0% | 2.2% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.4% | 5.1% | ||
| Q4 24 | 2.1% | 1.1% | ||
| Q3 24 | 1.3% | 2.4% | ||
| Q2 24 | 2.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.09× | — | ||
| Q3 25 | -1.17× | 11.20× | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | -0.32× | 7.37× | ||
| Q4 24 | 17.56× | — | ||
| Q3 24 | 3.48× | — | ||
| Q2 24 | 2.86× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IIIN
| Welded Wire Reinforcement | $108.4M | 68% |
| PC Strand | $51.6M | 32% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
